Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 3
2005 1
2006 2
2009 5
2010 3
2011 4
2012 3
2013 2
2014 4
2015 6
2016 7
2017 8
2018 9
2019 4
2020 6
2021 3
2022 5
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Results by year

Filters applied: . Clear all
Page 1
Metal Drugs and the Anticancer Immune Response.
Englinger B, Pirker C, Heffeter P, Terenzi A, Kowol CR, Keppler BK, Berger W. Englinger B, et al. Among authors: pirker c. Chem Rev. 2019 Jan 23;119(2):1519-1624. doi: 10.1021/acs.chemrev.8b00396. Epub 2018 Nov 29. Chem Rev. 2019. PMID: 30489072 Review.
Blocking STAT3/5 through direct or upstream kinase targeting in leukemic cutaneous T-cell lymphoma.
Sorger H, Dey S, Vieyra-Garcia PA, Pölöske D, Teufelberger AR, de Araujo ED, Sedighi A, Graf R, Spiegl B, Lazzeri I, Braun T, Garces de Los Fayos Alonso I, Schlederer M, Timelthaler G, Kodajova P, Pirker C, Surbek M, Machtinger M, Graier T, Perchthaler I, Pan Y, Fink-Puches R, Cerroni L, Ober J, Otte M, Albrecht JD, Tin G, Abdeldayem A, Manaswiyoungkul P, Olaoye OO, Metzelder ML, Orlova A, Berger W, Wobser M, Nicolay JP, André F, Nguyen VA, Neubauer HA, Fleck R, Merkel O, Herling M, Heitzer E, Gunning PT, Kenner L, Moriggl R, Wolf P. Sorger H, et al. Among authors: pirker c. EMBO Mol Med. 2022 Dec 7;14(12):e15200. doi: 10.15252/emmm.202115200. Epub 2022 Nov 7. EMBO Mol Med. 2022. PMID: 36341492 Free PMC article.
Anticancer metal drugs and immunogenic cell death.
Terenzi A, Pirker C, Keppler BK, Berger W. Terenzi A, et al. Among authors: pirker c. J Inorg Biochem. 2016 Dec;165:71-79. doi: 10.1016/j.jinorgbio.2016.06.021. Epub 2016 Jun 16. J Inorg Biochem. 2016. PMID: 27350082 Review.
The Lipid Metabolism as Target and Modulator of BOLD-100 Anticancer Activity: Crosstalk with Histone Acetylation.
Baier D, Mendrina T, Schoenhacker-Alte B, Pirker C, Mohr T, Rusz M, Regner B, Schaier M, Sgarioto N, Raynal NJ, Nowikovsky K, Schmidt WM, Heffeter P, Meier-Menches SM, Koellensperger G, Keppler BK, Berger W. Baier D, et al. Among authors: pirker c. Adv Sci (Weinh). 2023 Nov;10(32):e2301939. doi: 10.1002/advs.202301939. Epub 2023 Sep 26. Adv Sci (Weinh). 2023. PMID: 37752764 Free PMC article.
A novel EGFR inhibitor acts as potent tool for hypoxia-activated prodrug systems and exerts strong synergistic activity with VEGFR inhibition in vitro and in vivo.
Caban M, Koblmueller B, Groza D, Schueffl HH, Terenzi A, Tolios A, Mohr T, Mathuber M, Kryeziu K, Jaunecker C, Pirker C, Keppler BK, Berger W, Kowol CR, Heffeter P. Caban M, et al. Among authors: pirker c. Cancer Lett. 2023 Jul 1;565:216237. doi: 10.1016/j.canlet.2023.216237. Epub 2023 May 19. Cancer Lett. 2023. PMID: 37211067 Free article.
Krebs von den Lungen 6 (KL-6) is a novel diagnostic and prognostic biomarker in pleural mesothelioma.
Stockhammer P, Baumeister H, Ploenes T, Bonella F, Theegarten D, Dome B, Pirker C, Berger W, Hegedüs L, Baranyi M, Schuler M, Deshayes S, Bölükbas S, Aigner C, Blanquart C, Hegedüs B. Stockhammer P, et al. Among authors: pirker c. Lung Cancer. 2023 Nov;185:107360. doi: 10.1016/j.lungcan.2023.107360. Epub 2023 Sep 7. Lung Cancer. 2023. PMID: 37713954 Free article.
Mesothelioma-associated fibroblasts enhance proliferation and migration of pleural mesothelioma cells via c-Met/PI3K and WNT signaling but do not protect against cisplatin.
Ries A, Flehberger D, Slany A, Pirker C, Mader JC, Mohr T, Schelch K, Sinn K, Mosleh B, Hoda MA, Dome B, Dolznig H, Krupitza G, Müllauer L, Gerner C, Berger W, Grusch M. Ries A, et al. Among authors: pirker c. J Exp Clin Cancer Res. 2023 Jan 23;42(1):27. doi: 10.1186/s13046-022-02582-0. J Exp Clin Cancer Res. 2023. PMID: 36683050 Free PMC article.
Targeting fibroblast growth factor receptors to combat aggressive ependymoma.
Lötsch D, Kirchhofer D, Englinger B, Jiang L, Okonechnikov K, Senfter D, Laemmerer A, Gabler L, Pirker C, Donson AM, Bannauer P, Korbel P, Jaunecker CN, Hübner JM, Mayr L, Madlener S, Schmook MT, Ricken G, Maaß K, Grusch M, Holzmann K, Grasl-Kraupp B, Spiegl-Kreinecker S, Hsu J, Dorfer C, Rössler K, Azizi AA, Foreman NK, Peyrl A, Haberler C, Czech T, Slavc I, Filbin MG, Pajtler KW, Kool M, Berger W, Gojo J. Lötsch D, et al. Among authors: pirker c. Acta Neuropathol. 2021 Aug;142(2):339-360. doi: 10.1007/s00401-021-02327-x. Epub 2021 May 27. Acta Neuropathol. 2021. PMID: 34046693 Free PMC article.
Fibroblast growth factor receptor 4 promotes glioblastoma progression: a central role of integrin-mediated cell invasiveness.
Gabler L, Jaunecker CN, Katz S, van Schoonhoven S, Englinger B, Pirker C, Mohr T, Vician P, Stojanovic M, Woitzuck V, Laemmerer A, Kirchhofer D, Mayr L, LaFranca M, Erhart F, Grissenberger S, Wenninger-Weinzierl A, Sturtzel C, Kiesel B, Lang A, Marian B, Grasl-Kraupp B, Distel M, Schüler J, Gojo J, Grusch M, Spiegl-Kreinecker S, Donoghue DJ, Lötsch D, Berger W. Gabler L, et al. Among authors: pirker c. Acta Neuropathol Commun. 2022 Apr 28;10(1):65. doi: 10.1186/s40478-022-01363-2. Acta Neuropathol Commun. 2022. PMID: 35484633 Free PMC article.
80 results